News – Page 193 – Selby Spine

MAHWAH, N.J., May 24, 2017 /PRNewswire/ — Stryker Orthopaedics announced today plans to activate in Fort Worth, TX for the DEAN & DELUCA Invitational. For the second consecutive year appearing at the tournament, Stryker will continue to engage with fans through its onsite activation, The Mobility Zone – a destination designed to educate golf fans on the importance of joint health through various engaging activities. New for 2017, on Friday, Army Veteran Robert Baker, Stryker’s Vice President of Operations, will present one well-deserving military hero with a service dog in a special K9s For Warriors ceremony – marking the company’s third donation this year.

As an extension of a successful relationship that began last year, throughout the PGA TOUR® and PGA TOUR Champions 2017 season, Stryker will continue to give a new leash on life to military heroes by sponsoring service canines and empowering veterans to return to civilian life with dignity and independence. Tournament goers can also show their support to veterans by purchasing the same hat that PGA TOUR professionals and longtime brand ambassadors, Fred Funk and Hal Sutton wear on TOUR at the newly renovated Mobility Zone – Stryker’s premiere “joint health” destination. With each hat purchase, Stryker will make a donation to the K9s For Warriors organization.

This year marks the 71st anniversary of the tournament being held at Colonial Country Club – making it the longest running PGA TOUR event at the same venue. While on site, Stryker will showcase its commitment to educate Colonial’s dedicated tournament goers about the importance of leading an active lifestyle and having healthy joints. Inside The Mobility Zone, fans can partake in the new Stryker Challenge – a hands-on experience featuring Art H. Ritis, a life-size model that aims to provide tournament goers with a basic understanding of joint replacement surgery and Stryker’s products. In addition, fans who stop by The Mobility Zone will be able to enter for a chance to win a trip for two to Atlanta, GA for the TOUR Championship® and walk inside the ropes as an honorary observer – a true VIP experience.^1,2

“We are proud to continue to serve as a resource for fans onsite to learn about the importance of joint health, while also paying tribute to our brave service men and women,” said Bill Huffnagle, President, Stryker’s Joint Replacement Division. “Tournament goers can visit The Mobility Zone to support our military by purchasing a Stryker hat and learn more about joint health through fun activities and challenges.”

In an effort to reach fans both on and off the golf course, the company recently embarked on a cross- country road trip with brand ambassadors, NFL Hall of Famer Jerome Bettis and PGA TOUR Champions player and GetAroundKnee® patient, Fred Funk. The two have teamed up alongside Stryker to create a video series, demonstrating various ways to stay healthy and keep your joints moving. Earlier this month, Bettis and Funk stopped by Forth Worth to film the second episode of the video series where they went to the local batting cages to hit a few balls, and made a pit stop at the nation’s largest honky-tonk to learn how to line dance. To follow the “Road Trip to a Healthier Lifestyle” series and learn more about Stryker, visit StrykerChallenge.com.

Healthcare Professionals (HCPs) are not eligible to enter the Stryker Challenge Sweepstakes or participate in the any of these promotions. HCPs are defined as those individuals or entities involved in the provision of health care services and/or items to patients, which purchase, lease, recommend, use, arrange for the purchase or lease of, or prescribe Stryker’s products.
No purchase necessary to enter or win Sweepstakes. Void where prohibited by law. For official rules visit StrykerChallenge.com. Open to legal residents of the US & US Territories, 21+ as of date of entry. Sweepstakes begins at 12:01 am ET on 1/11/17 and ends at 11:59 pm ET on 8/27/17. Sponsored by Stryker.

About Stryker
Stryker is one of the world’s leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world.

About PGA TOUR
The PGA TOUR is the leading global platform in professional golf, showcasing the highest expression of excellence, both on and off the course. The PGA TOUR’s mission is to entertain and inspire its fans, deliver substantial value to its partners, create outlets for volunteers to give back, generate significant charitable and economic impact in the communities in which it plays, grow and protect the game of golf and provide financial opportunities for TOUR players.

The PGA TOUR co-sanctions more than 130 tournaments on the PGA TOUR, PGA TOUR Champions, Web.com Tour, PGA TOUR Latinoamérica, Mackenzie Tour-PGA TOUR Canada and PGA TOUR China. Its members represent the world’s best players, hailing from 24 countries (86 members are from outside the United States). Worldwide, PGA TOUR tournaments are broadcast to more than 1.1 billion households in 227 countries and territories in 23 languages. Virtually all tournaments are organized as non-profit organizations in order to maximize charitable giving. In 2016, tournaments across all Tours generated a record of more than $166 million for local and national charitable organizations, bringing the all-time total to $2.46 billion.

The PGA TOUR’s web site is PGATOUR.COM, the No. 1 site in golf, and the organization is headquartered in Ponte Vedra Beach, Fla.

SOURCE Stryker

May 24, 2017

JACKSONVILLE, Fla.–(BUSINESS WIRE)–NovaBone Products, a leading biologics medical device company, announces the addition of NovaBone IRM and NovaBone IRM MacroPOR to its portfolio of biologically active bone graft substitutes.

NovaBone IRM, and NovaBone IRM MacroPOR are the most advanced bioactive synthetic bone graft substitutes available to the orthopedic community today. Both formulations optimize osteogenesis, uniquely signal and stimulate osteoblastic activity, and offer angiogenic potential. By design, both formulations are highly irrigation resistant with excellent cohesion and handling properties.

“NovaBone Products’ base Bioactive Glass technology has proven to out-perform traditional calcium sulfate based synthetic products and demineralized bone matrix products,” said Dennis McBride, Vice President of Sales and Marketing. “We are now advancing our science further by providing formulations with carriers that have a synergistic effect in bone formation and retain molded shapes following implantation and irrigation.”

Novabone offers the broadest portfolio of bioactive synthetic bone graft substitutes in the world, with a robust pipeline of products in development designed to expand the regenerative biologics products the company offers. Presently, products offered include minimally invasive (MIS) delivery devices, strip formulations, putty materials that are hydrated using bone marrow aspirate, and putty formulations that are ready-to-use out of the package.

“We are proud to offer products that allow a surgeon to look to one company when addressing bone grafting needs,” concluded McBride.

NovaBone Products, a privately held company based in Florida, USA since 2002 and a recognized industry leader in bioactive glass design and manufacturing, developed the first bioactive synthetic bone graft offered to the orthopaedic community.

Contacts

NovaBone Products
Arthur Wotiz, President
904-651-0607
awotiz@novabone.com

DALLAS, TEXAS, USA, May 24, 2017 /EINPresswire.com/ — Gramercy Extremity Orthopedics (GEO) is pleased to announce the first surgery using the GEO™ Bone Screw and GEO CART™ systems. The first surgery was performed by Dr. Peter A. Blume, D.P.M., F.A.C.F.A.S. at Shoreline Surgery Center LLC, Guilford, CT, with outstanding results. As the first offering in the company’s product line, this marks a major milestone for Gramercy Extremity Orthopedics™.

Dr. Blume remarked on the advantages of the GEO™ Bone Screw and GEO CART™ Systems, “I was extremely impressed and pleased with the outcome when utilizing the GEO™ Bone Screw and GEO CART™ systems. The ease in which the system operated was noted by the entire Surgical Center staff and felt that the systems created many efficiencies that are lacking in today’s operating environment. The surgical back table was free of clutter and the implant and instruments were truly best of class. The GEO CART™ finally addresses all the pitfalls when operating with orthopedic hardware, whether it be at the Surgery Center or in the hospital setting.”

The GEO CART™ proprietary point-of-sale system reduces delays in surgery, decreases sterility risks to the patient, eliminates billing mistakes and hand written forms, automatically generates the Implant Usage Form and reduces facility operating expenses.

The GEO CART™ is a computerized mobile implant and instrumentation inventory system based on RFID technology. No bigger than the average medical cart, the GEO CART™ system can hold over 2,000+ items.

The GEO™ Bone Screw System offers a comprehensive array of low profile titanium screw lengths, diameters, thread lengths and fully threaded options. All GEO™ Bone Screws are double sterile packaged, self-drilling, self-tapping, reverse-cutting with variable length short and long threads and a hexalobe head to provide additional stability and torque transfer with less potential for head stripping. All instruments within the GEO™ Bone Screw system are also double sterile packaged in single use kits to ensure a new and sterilized instrument is used every surgery.

“We are all very pleased with the results from today’s surgery. Not only did the implant and instruments all work superbly, the case was performed without issue and in an efficient manner,” says Michael P. Simpson, President and CEO of Gramercy Extremity Orthopedics™. “As for the GEO CART™, in my 16 years in orthopedic medical devices, I have never had the ability to see the transactions remotely from a case within minutes of the surgery happening. This is a significant breakthrough in our industry. I want to thank the GEO™ team for all of their hard work in getting this system to the marketplace”

GEO™ will be exhibiting at the AOFAS Scientific Conference, Seattle, July 12-14, 2017. Booth #610.

About Gramercy Extremity Orthopedics™:

GEO™ was formed from the idea that there could exist a more cost-effective, user-friendly way to supply Orthopedic Medical Implants in today’s healthcare environment. This is accomplished through the use of RFID technology, a groundbreaking Point-of-Sale delivery system, and GEO™ designed best in class sterilized single-use orthopedic implants and instruments. GEO™ is the only solution that provides a significant opportunity to lower real operating costs by creating efficiencies and controls throughout the delivery and consumption of orthopedic implants.

Michael Nugent
Gramercy Extremity Orthopedics™
855-436-2278 ext 103
email us here

SOMERVILLE, N.J., May 24, 2017 /PRNewswire/ — Ethicon^* announced the results of two economic analyses demonstrating that the DERMABOND^®PRINEO^® Skin Closure system, a product that combines a topical skin adhesive with a self-adhering patch, is associated with improved patient outcomes and lower healthcare costs for hospitals. Both studies are being presented at the International Society for Pharmacoeconomics and Outcomes Research’s 22nd Annual International Meeting this week.

The first study, Comparison of Economic and Clinical Outcomes between the DERMABOND® PRINEO® Skin Closure System and Skin Staples in Patients Undergoing Knee Replacement in Real World Clinical Practice,¹ found that the DERMABOND PRINEO System is associated with improved outcomes for patients receiving total knee arthroplasty (TKA) when compared to skin staples. The findings are based on a retrospective analysis of 1,942 TKA procedures using the Premier Perspective^®Hospital Database. Specifically, the DERMABOND PRINEO System was associated with a statistically significant reduction in readmission rates at 30, 60 & 90 days, a reduction in length of hospital stay and a lower probability of being discharged to a skilled nursing facility (SNF). The analysis showed that the 30-day readmission rate for the DERMABOND PRINEO System group was 1.8%, compared to 4.4% for the skin staple group. The costs of 30 day readmissions for TKA have been estimated to be $12,839.² The DERMABOND PRINEO System was also associated with a 12% reduction in length of hospital stay and a 31% reduction in discharge to a SNF or other non-home setting, which could lead to savings in the acute and post-acute setting.

The second study, A U.S. Hospital Budget Impact Analysis of a Skin Closure System Compared with Standard of Care in Hip and Knee Arthroplasty, estimates the 90-day cost impact of the DERMABOND PRINEO System compared to other wound closure methods for hip and knee arthroplasty from a U.S. provider perspective.³ The analysis showed that the use of the DERMABOND PRINEO System DERMABOND PRINEO System in hip and knee arthroplasty may achieve cost savings that could translate into an annual hospital budgetary savings ranging from $28,349 to $39,809 when assuming 500 arthroplasties.³ The predicted cost savings was driven by reductions in dressing materials and post-operative healthcare visits when the DERMABOND PRINEO System is utilized.

“Ethicon is committed to bringing to market innovative products that are designed to provide improved outcomes for patients and enable our customers to provide the best care for their patients,” says Nefertiti Greene, Vice President, Global Wound Closure and Repair Platform Leader at Ethicon. “The DERMABOND PRINEO System has been shown by this research to be an excellent approach to wound closure.”

Reducing the length of a patient’s hospital stay can lead to reduced costs and may also lower the chances of contracting an infection.⁴In addition, reducing readmissions can prevent hospitals from being penalized for readmission rates above the national average for TKA.⁵ The reductions in health care resource utilization demonstrated in these studies are important for hospital systems and health care professionals particularly those who are part of or are considering episode-based payments where both acute and post-acute costs are combined into one payment.

Several benefits associated with the DERMABOND PRINEO System may explain the findings. The product provides significantly greater skin holding strength than skin staples and subcuticular suture,⁶⁺ and acts as a barrier to microbial penetration against organisms commonly associated with surgical site infection.⁷ The DERMABOND PRINEO System requires no postsurgical dressings which may mean easier self-care and greater self-confidence for patients.⁷ Also, if directed by their healthcare professional, patients can shower immediately after surgery⁷ which could lead to a higher level of patient satisfaction.

About Ethicon

From creating the first sutures to revolutionizing surgery with minimally invasive procedures, Ethicon, part of the Johnson & Johnson Medical Devices Companies, has made significant contributions to surgery for more than 60 years. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world’s most pressing health care issues, and improve and save more lives. Through Ethicon’s surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treating serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. Learn more at www.ethicon.com, and follow us on Twitter @Ethicon.

*Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates Ethicon, Inc. is the legal manufacturer of the DERMABOND^®PRINEO^® Skin Closure system. All other trademarks are the property of their respective owners.

+In an ex vivo study, more load in N was required to create a 3-mm gap between skin edges approximated with DERMABOND PRINEO System (22 cm) than with subcuticular 4-0 MONOCRYL® (poliglecaprone 25) Suture or PROXIMATE® Ethicon Endo-Surgery skin staples (P<.001).

073076-170517

¹Johnston S, Sutton N. Comparison of Economic and Clinical Outcomes between the Dermabond® Prineo® Skin Closure System and Skin Staples in Patients Undergoing Knee Replacement in Real World Clinical Practice. Poster Presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.
² HCUP Statistical Briefs website. Available at: https://www.hcup-us.ahrq.gov/reports/statbriefs/sbtopic.jsp. Accessed May 17, 2017
³ Sadik, K, Flener J, Gargiulo J, Graves M, Nunley, R Post, Z, Wurzelbacher, Sutton, N, Hogan, Hollman, S, Ferko, N. A U.S. Hospital Budget Impact Analysis of a Skin Closure System Compared with Standard of Care in Hip and Knee Arthroplasty. Poster Presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.
⁴ Hassan M, Tuckman HP, Patrick RH, Kountz DS, Kohn JL. Hospital length of stay and probability of acquiring infection. International Journal of Pharmaceutical and Healthcare Marketing. 2010;4(4):324-338.
⁵ Centers for Medicare & Medicaid Services Readmissions Reduction Program (HRRP) https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program.html. Accessed May 17, 2017.
⁶ Data on file, Ethicon, Inc.: Kumar A. AST-2012- 0290. Completion Report: Study to compare the tissue holding strength of PRINEO Skin Closure System with conventional wound closure techniques. 2012.
⁷ Data on file. Ethicon, Inc. Dermabond Prineo System Master Claims Matrix.

SOURCE Ethicon

LONG BEACH, Calif., May 24, 2017 /PRNewswire-USNewswire/ — The MemorialCare Joint Replacement Center at Long Beach Memorial is the first hospital in Long Beach and North Orange County to offer Stryker’s robotic-arm assisted total knee application for use with its Mako System – and now has successfully performed its first total knee replacement case in that region using this new technology. This latest advancement in joint replacement surgery transforms the way total knee replacements are performed.

Total knee replacements in the United States are expected to increase 673 percent by 2030,¹ yet studies have shown that approximately 30 percent of patients are dissatisfied after conventional surgery.² Mako Total Knee combines Stryker’s advanced robotic technology with its clinically proven GetAroundKnee (Triathlon Total Knee System), which enabled surgeons to have a more predictable surgical experience with increased accuracy during laboratory testing.³

“Mako is changing the way joint replacement surgeries are performed by providing each patient with a personalized surgical experience based on their specific diagnosis and anatomy,” said Andrew Wassef, M.D., medical director, MemorialCare Joint Replacement Center, Long Beach Memorial. “Using a virtual 3D model, the Mako System allows surgeons to create each patient’s surgical plan pre-operatively before entering the operating room. During surgery, the surgeon can validate that plan and make any necessary adjustments while guiding the robotic-arm to execute that plan. It’s exciting to be able to offer this transformative technology across the joint replacement service line to perform total knee, total hip and partial knee replacements.”

The Mako Total Knee application is a knee replacement treatment option designed to relieve the pain caused by joint degeneration due to osteoarthritis. Through CT-based 3D modeling of bone anatomy, surgeons can use the Mako System to create a personalized surgical plan and identify the implant size, orientation and alignment based on each patient’s unique anatomy. The Mako System also enables surgeons to virtually modify the surgical plan intra-operatively and assists the surgeon in executing bone resections.

“We are proud to be the first hospital to offer this highly advanced robotic technology in our area,” said Tamra Kaplan, PharmD, chief operating officer, Long Beach Memorial. “This addition to our orthopaedic service line further demonstrates our commitment to provide the community with outstanding healthcare.”

About the MemorialCare Joint Replacement Center at Long Beach Memorial:

Long Beach Memorial is lauded for superior clinical quality outcomes and has been listed on U.S. News & World Report’s America’s Best Hospitals since the annual rankings began. In this year’s results, Long Beach Memorial received “high performance” rankings in nine clinical specialty areas, including Hip Replacement, Knee Replacement and Orthopedics. It also is among a small percentage of U.S. hospitals consistently recognized for outstanding dedication to patient safety by maintaining a top “A” grade in eight of nine Leapfrog Group Hospital Safety Score evaluations for its ability to prevent errors, injuries, accidents and infections.

JRC specializes in a rapid rehabilitation program – where patients walk the same day of surgery – resulting in a shorter hospital stay – average hospital stay is zero to two days. The JRC features a dedicated unit for joint replacement patients with 15 private rooms, a joint care coordinator to help patients navigate through the program, patient education before and after surgery and “rehab coaches” to provide support as patients take their first steps toward an active lifestyle.

1. Kurtz AAOS. Total knee and hip replacement projections 2030. www.prnewswire.com/news-releases/total-knee and-hip-replacement-surgery projections-show-meteoric-rise-by-2030-55519727.html. Accessed July 4, 2016. 2. Christiaan Keurentjes J, Fiocco M, So-Osman C, et al. Patients with severe radiographic osteoarthritis have better prognosis in physical functioning after hip and knee replacement: a cohort-study. PLOS One. 2013; 8(4): 1-8. 3. Hampp EL, Scholl LY, Prieto M, Chang T, Abbasi AZ, Bhowmik-Stoker M, Otto JK, Jacofsky DJ, Mont MA. “Accuracy Assessment of Robotic and Manual TKA in a Cadaveric Model.” Robotic-arm assisted total knee arthroplasty demonstrated greater accuracy to plan compared to manual technique. ORS 2017 Annual Meeting. San Diego. Poster No.2412.

SOURCE Long Beach Memorial

boston-scientific-marlborough-1200xx1598-899-209-0-1200x675.jpg

Max Stendahl, Biotech Reporter / Boston Business Journal – May 4, 2017

The last five years have seen a flurry of dealmaking in the medical device industry. And according to a new report, Marlborough-based Boston Scientific is responsible for more acquisitions than any other company since 2012 except one.

With 27,000 employees worldwide and around 2,500 here in Massachusetts, Boston Scientific (NYSE: BSX) is the largest medical device firm based in the state by headcount. It’s pulled off eight acquisitions since the beginning of 2012, according to the report by market research firm CB Insights. (The actual number appears to be 10; the report appears to omit one recent deal for an endoscopy firm and another in 2014 for a manufacturer.)

The only medical device company that was more active during this period was Boston Scientific’s rival, Ireland-based Medtronic (NYSE: MDT), which acquired a whopping 15 device firms.

For Boston Scientific, the string of acquisitions has coincided with the tenure of Mike Mahoney, who joined as president in October 2011 and was named CEO a year later. Boston Scientific has seen its stock price increase steadily with the 52-year-old Mahoney at the helm. He remains one of the highest-paid executives among public companies in the state, earning $35.7 million in total compensation plus value realized from past stock awards in 2016.

READ THE REST HERE

By Jonathan Saltzman – GLOBE STAFF MAY 24, 2017

A prominent Boston neurosurgeon was illegally forced out of his previous job at a New York hospital for strongly objecting to a policy that allowed another surgeon to perform complex spine surgeries on two patients simultaneously, a judge ruled.

Double-booking, as the practice is sometimes called, triggered a fierce dispute among doctors at Massachusetts General Hospital in recent years, leading to the 2015 dismissal of an orthopedic surgeon who opposed it. But Dr. James Holsapple may be the first doctor to win a lawsuit alleging he faced retaliation for challenging the practice.

New York Supreme Court Justice James P. Murphy ruled after a bench trial that University Hospital in Syracuse retaliated against Holsapple after he spoke out about the surgeon running two operating rooms at once.

“Dr. Holsapple vehemently objected and opposed the procedures for valid public health and safety reasons,” Murphy ruled in a 13-page decision received by the neurosurgeon Monday.

Holsapple, now chief of neurosurgery at Boston Medical Center, was awarded $88,277 in lost wages under the New York State whistle-blower statute. His lawyer estimated that the award could top $150,000 because Holsapple is entitled to interest on lost wages.

Holsapple, who resigned under pressure from University Hospital in 2009 and moved to Boston, said he felt vindicated.

“I did what I thought was right, and I’m grateful that the judge who heard the case saw it the same way,” said Holsapple, who heads the neurosurgery department at the Boston University School of Medicine.

The New York attorney general’s office, which defended University Hospital as part of the State University of New York, referred all questions to the hospital. Darryl Geddes, a hospital spokesman, said he could not comment because the attorney general’s office is considering an appeal.

READ THE REST HERE

May 23, 2017

WESTMINSTER, Colo.–(BUSINESS WIRE)–ReedGroup®, a leading international provider of health and productivity solutions, is today announcing the National Guideline Clearinghouse (NGC)—a program of the federal Agency for Healthcare Research and Quality (AHRQ)—has accepted ReedGroup’s MDGuidelines® for Low Back Disorders and Cervical and Thoracic Spine Disorders.

The NGC uses exacting criteria to objectively review guidelines, and publishes only guidelines that meet the Institute of Medicine’s (IOM) criteria for transparent, reproducible, high-quality guidelines. In 2014, the NGC revised its guideline inclusion criteria to align with advances in Clinical Practice Guidelines We Can Trust (CPG) development, and the revised inclusion criteria reflect the IOM’s more rigorous standards.

In addition to meeting NGC’s guideline inclusion criteria, ReedGroup’s MDGuidelines were held up against the IOM’s Systematic Review (SR), which comprehensively evaluates evidence and takes into account search strategies, study descriptions, syntheses and summaries of evidence, systematic review bases, and more. MDGuidelines also were evaluated to ensure they maintained documentation demonstrating each guideline’s recommendations considered the assessment of benefits and harms of recommended care and alternative care options.

MDGuidelines incorporates the gold standard ACOEM Practice Guidelines that provide evidence-based recommendations for diagnostic and treatment practices and are based upon a systematic review of evidence, and its recommendations optimize patient care and assist health care providers and patients in making decisions about appropriate health care. The ACOEM Practice Guidelines adhere to the highest standards set forth by the IOM, AGREE II, AMSTAR, and GRADE.

“In our view, the NGC is doing great work to ensure that U.S. healthcare providers are given the best evidence-based guidelines, and MDGuidelines is honored to be a part of that,” said Joe Guerriero, senior vice president of MDGuidelines at ReedGroup. “The requirements of value-based care continue to heighten so healthcare organizations, employers and all industry stakeholders need a clear and proven treatment roadmap for their patients and employees. This means the guidelines used must truly be evidence-based, otherwise, the safety of U.S. workers is at stake.”

Learn more about MDGuidelines.

About ReedGroup

ReedGroup, a wholly owned subsidiary of The Guardian Life Insurance Company of America®, is a leading health and productivity organization providing services to over half of the Fortune 100 companies. With more than 2000 employees, ReedGroup has operations across the United States, Canada, and India. ReedGroup’s flagship product, MDGuidelines, is the industry’s leading solution for total health management and workplace productivity. MDGuidelines features the world’s most trusted disability duration estimates and evidence-based Practice Guidelines from ACOEM. MDGuidelines is a proven approach to managing and measuring the impact of evidence-based care across entire populations.

Contacts

ReedGroup
Tracy Dunagan, 303-246-3308
tracy.dunagan@reedgroup.com

PLAINSBORO, N.J. and BERLIN, May 23, 2017 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, announced today that it has signed an agreement with aap Implantate AG (“aap”) to distribute the LOQTEQ® Distal Radius System within the United States. Berlin-based aap is a globally operating medical device company developing, manufacturing and marking trauma products for orthopedics.

“Integra is a leader in the hand and wrist arthroplasty market,” said Bob Davis, corporate vice president and president, Orthopedics and Tissue Technologies. “Adding a wrist plating system to our portfolio elevates Integra into a one-stop solution for our customers’ wrist needs- from fracture plating to fusion and arthroplasty.”

The LOQTEQ® distal radius system features state-of-the-art designs with multiple plate options to accommodate a variety of fracture patterns and anatomies, as well as instrumentation designed for intra-operative efficiency.

Bruke Seyoum Alemu, CEO of aap, said, “We are looking forward to expanding our footprint in the US with a proven force in the upper extremity field. The alliance between aap and Integra is a natural fit for both companies and will additionally drive our dynamic development in North America.”

Integra’s industry-leading products in the upper extremity market include the Freedom Wrist Arthroplasty System and the PyroCarbon MCP prosthesis.

About Integra
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, and orthopedics and tissue technologies. For more information, please visit www.integralife.com.

About aap
aap’s aspiration is to make trauma treatment better and cost-effective through innovations dedicated to create a sustainable value for patients, surgeons and hospitals. The company provides a comprehensive plates and screws portfolio for mainstream trauma and has a pipeline with new innovative products. aap’s IP-protected core platform technologies are the LOQTEQ® locking compression technology, its antimicrobial silver coating technology and its resorbable coated magnesium implants technology. For more information, please visit www.aap.de.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: 
Integra LifeSciences Holdings Company

Investors
Nora Brennan                                    
609-936-2488                           
nora.brennan@integralife.com

Michael Beaulieu
609-750-2827
michael.beaulieu@integralife.com

Media
Laurene Isip
609-750-7984 
laurene.isip@integralife.com

aap Implantate AG

Fabian Franke 
+49 (0)30 / 750 19 134
f.franke@aap.de

SUWANEE, GA–(Marketwired – May 23, 2017) – SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the company’s exclusive distributor in Italy, Medical Advanced Technologies S.R.L. (MATEK) is sponsoring a one day scientific program to be conducted in Milan, Italy on May 26, 2017. This program, Workshop@Rooftop, will be held at the exclusive Hotel The Square in Milan. MATEK has been one of SANUWAVE’s most active partners in promoting both dermaPACE® and orthoPACE® in Europe. Their innovative and proactive approach towards promoting dermaPACE and orthoPACE is reflected in this program which will assemble some of the most accomplished medical researchers and medical practitioners in Italy. The program will discuss the newest clinical information related to the mechanism of action for SANUWAVE’s product line and to discuss clinical case-studies and on-going research in the field of extracorporeal shock wave technology (ESWT) and in particular the use of dermaPACE for wound indications and orthoPACE for orthopedic indications. Specific topics include:

Update on mechanism of action: from mechanobiology to the clinical practice, M.C., D’Agostino
Shock Wave Therapy for Myofascial Syndrome “Trigger Point”, A. Previtera
Update about international guidelines and new therapeutic frontiers, E. Tibalt

MATEK, with headquarters in Milan, Italy, has long been SANUWAVE’s partner in Italy. With their strength, experience and knowledge of the orthopedics and the wound care market, they are well positioned to help expand SANUWAVE’s market penetration via increased clinical presence and to continue to promote the company’s core products, dermaPACE and orthoPACE. “MATEK, once again, is setting the stage for creativity in furthering the field of ESWT. They are a model, not just in Italy, but in all of Europe, for how to create excitement and discussion among clinical researchers and practitioners alike.” stated Mr. Richardson, Chief Executive Officer of SANUWAVE. “We are extremely fortunate to have MATEK as a key team member in promoting our products abroad.”

For information related to MATEK’s Scientific Program, contact Ms. Annalisa Ali by email at commerciale@mateksrl.com or by telephone at +39 02 87264725.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (OTCQB: SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s de novo petition review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

About MATEK

Operating since 2010 in the field of medical instruments, MATEK s.r.l. is the exclusive distributor in Italy of the products manufactured by SANUWAVE Inc., an emerging US-based regenerative medicine company. With the support of its specialized technical experts and qualified professionals, MATEK s.r.l. supplies its customers with electrohydraulic focused shock wave generators. This technique has been proven to have a high success rate in the treatment of soft tissue and bone diseases. MATEK’s mission is to provide users of medical devices, and in particular of focused shock wave generators, all-inclusive support to ensure consistently high quality levels even with intensive use. We offer training courses, assistance in promoting the presence and use of the medical device, medical/scientific support and technical/administrative information in relationships with the competent health authorities.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit www.sanuwave.com.

CONTACT INFORMATION

Contact:
Millennium Park Capital LLC
Christopher Wynne
312-724-7845
cwynne@mparkcm.com

SANUWAVE Health, Inc.
Kevin Richardson II
Chairman of the Board
978-922-2447
investorrelations@sanuwave.com

Newer Posts

Older Posts

Search

3 days / 6 sessions
Current Issues in Spine

Stryker Returns To DEAN & DELUCA Invitational For Second Consecutive Year With Plans To Honor Military Veteran With Service Canine

NovaBone Announces Irrigation Resistant Products with Carriers that have Synergistic Effect in Bone Formation

Contacts

First Surgery Completed Utilizing the Gramercy Extremity Orthopedic™ Systems

DERMABOND® PRINEO® Skin Closure System May Improve Outcomes and Lower Hospital Costs

MemorialCare Joint Replacement Center At Long Beach Memorial Now Offering Newest Technology In Total Knee Replacement

Boston Scientific is the 2nd biggest dealmaker in medtech since 2012

Doctor who faced retaliation for raising concerns about double-booked surgeries wins lawsuit

Agency for Healthcare Research and Quality Accepts ReedGroup’s MDGuidelines

Contacts

Integra LifeSciences Announces Agreement with aap to Distribute LOQTEQ® Distal Radius System

SANUWAVE Health Announces Shock Wave Scientific Program in Milan, Italy Conducted by Medical Advanced Technologies, 26 May, 2017

CONTACT INFORMATION

STAR Ankle Joint Replacements Last Long Term and Provide Relief for Patients

Medacta USA’s Spine Division Begins 2017 with Key Appointment, Significant Growth

Spinal Stabilization Technologies Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease

$250K Pediatric Device Competition Now Accepting Proposals

First Single-Use Rigid Endoscope to be Demonstrated at AAOS